A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.
News & Analysis: Sorrento Therapeutics
From an analyst downgrade to new tariffs on China, see why these three companies fell on Thursday.
The biotech's share price dropped on no news -- but perhaps plenty of worries.
A recent fundraising effort has investors running for the exits.
A sell-the-news 24% drop. Oh my!
These biotechs have promising pipeline candidates -- but can their sizzling stock momentum continue?
Investors crowd into the biotech ahead of a potential approval at the end of the month.
Investors can address their thank you notes to Celgene's management.
Celgene appears to have lit a fire beneath all three of these small biotech stocks.
3D bioprinting is an amazing advance in biotechnology, but with their slightly less sci-fi offerings, Agenus and Sorrento just might emerge as bigger winners for investors than Organovo. Here's why: